Drug
Brenetafusp
Brenetafusp: highest development phase Phase 3, developed by Immunocore. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Immunocore
Trials
| Drug | Phase | Indication |
|---|---|---|
| Brenetafusp NCT06112314 | Phase 3 | Advanced Melanoma |
| Brenetafusp NCT04262466 | Phase 1/2 | Select Advanced Solid Tumors |
Latest
No recent events.
Follow Brenetafusp on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.